JPH09504529A - 安定化したプロスタグランジンe▲下1▼ - Google Patents
安定化したプロスタグランジンe▲下1▼Info
- Publication number
- JPH09504529A JPH09504529A JP7512604A JP51260495A JPH09504529A JP H09504529 A JPH09504529 A JP H09504529A JP 7512604 A JP7512604 A JP 7512604A JP 51260495 A JP51260495 A JP 51260495A JP H09504529 A JPH09504529 A JP H09504529A
- Authority
- JP
- Japan
- Prior art keywords
- pge
- formulation
- lactose
- freeze
- butyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.a)ラクトースおよび第三級ブチルアルコールの溶液にPGE-1を溶解し 、ここに、該第三級ブチルアルコールは約15%〜約33%容量/容量の量で存 在し、かつラ該クトースのPGE-1に対する比は約40,000対1〜約10, 000対1重量/重量であり、それによってラクトース中に分散したPGE-1処 方が形成され; b)該処方のpHを有機酸緩衝液で約3.6〜約6に調整し維持し; c)該処方を約-50℃に凍結し;次いで d)該処方を乾燥して、1乾燥重量%未満の水分含量であって、3乾燥重量% 未満の第三級ブチルアルコール含量とする; ことよりなるプロセスにより製造されるPGE-1の凍結乾燥処方。 2.該工程c)に、該処方を約-50℃に凍結した後に、約2時間で約-25℃ま で加温し、次いで約-50℃に再凍結することが包含される請求項1記載のプロ セスにより製造されるPGE-1の凍結乾燥処方。 3.該工程b)の有機酸緩衝液がクエン酸ナトリウムである請求項1記載のプロ セスにより製造されるPGE-1の凍結乾燥処方。 4.PGE-1がラクトース中に約25〜約100ppmの量で存在する請求項 1記載のプロセスにより製造されるPGE-1の凍結乾燥処方。 5.該工程b)が、該処方のpHを有機酸緩衝液で4〜5に調整して維持するこ とである請求項1記載のプロセスにより製造されるPGE-1の凍結乾燥処方。 6.a)ラクトースおよび第三級ブチルアルコールの溶液にPGE-1を溶解さ せ、ここに、該第三級ブチルアルコールは約15%〜約33%容量/容量の量で 存在し、かつ、該ラクトースのPGE-1に対する比は約40,000対1〜約1 0,000対1重量/重量であり、それによってラクトース中に分散したPGE- 1処方が形成され; b)該処方のpHを有機酸緩衝液で約3.6〜約6に調整し維持し; c)該処方を約-50℃に凍結し;次いで d)該処方を乾燥して、1乾燥重量%未満の水分含量であって、3乾燥重量% 未満の第三級ブチルアルコール含量とする; 工程よりなる安定化した、PGE-1の凍結乾燥処方の製法。 7.該工程c)に、該処方を-50℃に凍結させた後に、約2時間で約-25℃ま で加温し、次いで約-50℃に再凍結することが包含される請求項6記載の方法 。 8.工程b)の該有機酸緩衝液がクエン酸ナトリウムである請求項6記載の方法 。 9.PGE-1がラクトース中に約25〜約100ppmの量で存在する請求項 6記載の方法。 10.工程b)が、該処方のpHを有機酸緩衝液で4〜5に調整して維持するこ とである請求項6記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14369593A | 1993-10-27 | 1993-10-27 | |
US08/143,695 | 1993-10-27 | ||
PCT/US1994/009648 WO1995011683A1 (en) | 1993-10-27 | 1994-09-06 | Stabilized prostaglandin e¿1? |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09504529A true JPH09504529A (ja) | 1997-05-06 |
JP3999263B2 JP3999263B2 (ja) | 2007-10-31 |
Family
ID=22505188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51260495A Expired - Lifetime JP3999263B2 (ja) | 1993-10-27 | 1994-09-06 | 安定化したプロスタグランジンe▲1▼ |
Country Status (16)
Country | Link |
---|---|
US (2) | US5741523A (ja) |
EP (1) | EP0725642B1 (ja) |
JP (1) | JP3999263B2 (ja) |
KR (1) | KR100335549B1 (ja) |
CN (1) | CN1060042C (ja) |
AT (1) | ATE187071T1 (ja) |
AU (1) | AU688792B2 (ja) |
DE (1) | DE69421936T2 (ja) |
DK (1) | DK0725642T3 (ja) |
ES (1) | ES2142409T3 (ja) |
FI (1) | FI116270B (ja) |
GR (1) | GR3032817T3 (ja) |
NO (1) | NO309126B1 (ja) |
NZ (1) | NZ273752A (ja) |
PT (1) | PT725642E (ja) |
WO (1) | WO1995011683A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006096761A (ja) * | 1998-03-03 | 2006-04-13 | Shionogi & Co Ltd | ホスホリパーゼ阻害剤の[[3−(2−アミノ−1,2−ジオキソエチル)−2−エチル−1−フェニルメチル)−1h−インドール−4−イル]オキシ]酢酸ナトリウムを含む薬学的組成物 |
WO2006075690A1 (ja) * | 2005-01-14 | 2006-07-20 | Ono Pharmaceutical Co., Ltd. | 安定な医薬組成物 |
JP2007509989A (ja) * | 2003-10-31 | 2007-04-19 | ポイント バイオメディカル コーポレイション | 超音波造影剤として有用な再構成可能なミクロスフィア組成物 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
KR100195348B1 (ko) * | 1996-10-31 | 1999-06-15 | 장용택 | 안정한 프로스타글란딘 e1-함유 주사제 조성물 |
JP2001509480A (ja) | 1997-07-09 | 2001-07-24 | アンドロソリューションズ,インク. | 男性勃起機能不全を治療するための改良された方法及び組成物 |
US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6264981B1 (en) † | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
EP2266590A3 (en) | 2002-02-22 | 2011-04-20 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
JP2008519047A (ja) * | 2004-11-05 | 2008-06-05 | セフアロン・インコーポレーテツド | 癌処置 |
US7582312B2 (en) * | 2004-11-15 | 2009-09-01 | Discovery Laboratories, Inc. | Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof |
US7464012B2 (en) * | 2004-12-10 | 2008-12-09 | L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude | Simplified process simulator |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
US9005183B2 (en) * | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
US20100222785A1 (en) * | 2007-08-03 | 2010-09-02 | Vanderbilt University | Anchor driver |
AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
EP2889029A1 (en) * | 2008-09-25 | 2015-07-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
UA109109C2 (uk) * | 2009-01-15 | 2015-07-27 | Сефалон, Інк. | Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти) |
CA2787568C (en) | 2010-01-28 | 2019-04-02 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US10342769B2 (en) | 2014-11-14 | 2019-07-09 | Navinta Iii Inc | Carmustine pharmaceutical composition |
AT518009A1 (de) * | 2015-07-27 | 2017-06-15 | Gebro Holding Gmbh | Konzentrat enthaltend Alprostadil |
CN109394704B (zh) * | 2018-11-27 | 2021-09-17 | 西安力邦肇新生物科技有限公司 | 一种前列腺素e1甲酯注射用冻干制剂及制备和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3927197A (en) * | 1974-04-19 | 1975-12-16 | Pfizer | Tertiary alcohol stabilized E-series prostaglandins |
US3952004A (en) * | 1974-06-18 | 1976-04-20 | Pfizer Inc. | Stabilized E-series prostaglandins |
US4113882A (en) * | 1974-10-21 | 1978-09-12 | Yamanouchi Pharmaceutical Co., Ltd. | Stabilized oral prostaglandin formulation and the process for the preparation thereof |
AU617678B2 (en) * | 1987-05-22 | 1991-12-05 | Liposome Company, Inc., The | Prostaglandin-lipid formulations |
-
1994
- 1994-09-06 US US08/619,690 patent/US5741523A/en not_active Expired - Lifetime
- 1994-09-06 EP EP94927958A patent/EP0725642B1/en not_active Expired - Lifetime
- 1994-09-06 DK DK94927958T patent/DK0725642T3/da active
- 1994-09-06 CN CN94193888A patent/CN1060042C/zh not_active Expired - Fee Related
- 1994-09-06 DE DE69421936T patent/DE69421936T2/de not_active Expired - Lifetime
- 1994-09-06 WO PCT/US1994/009648 patent/WO1995011683A1/en active IP Right Grant
- 1994-09-06 KR KR1019960702158A patent/KR100335549B1/ko not_active IP Right Cessation
- 1994-09-06 PT PT94927958T patent/PT725642E/pt unknown
- 1994-09-06 JP JP51260495A patent/JP3999263B2/ja not_active Expired - Lifetime
- 1994-09-06 ES ES94927958T patent/ES2142409T3/es not_active Expired - Lifetime
- 1994-09-06 NZ NZ273752A patent/NZ273752A/en not_active IP Right Cessation
- 1994-09-06 AT AT94927958T patent/ATE187071T1/de not_active IP Right Cessation
- 1994-09-06 AU AU77167/94A patent/AU688792B2/en not_active Ceased
-
1996
- 1996-04-26 FI FI961797A patent/FI116270B/fi active IP Right Grant
- 1996-04-29 NO NO961718A patent/NO309126B1/no not_active IP Right Cessation
- 1996-12-30 US US08/777,132 patent/US5770230A/en not_active Expired - Lifetime
-
2000
- 2000-02-29 GR GR20000400524T patent/GR3032817T3/el not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006096761A (ja) * | 1998-03-03 | 2006-04-13 | Shionogi & Co Ltd | ホスホリパーゼ阻害剤の[[3−(2−アミノ−1,2−ジオキソエチル)−2−エチル−1−フェニルメチル)−1h−インドール−4−イル]オキシ]酢酸ナトリウムを含む薬学的組成物 |
JP2007509989A (ja) * | 2003-10-31 | 2007-04-19 | ポイント バイオメディカル コーポレイション | 超音波造影剤として有用な再構成可能なミクロスフィア組成物 |
WO2006075690A1 (ja) * | 2005-01-14 | 2006-07-20 | Ono Pharmaceutical Co., Ltd. | 安定な医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
WO1995011683A1 (en) | 1995-05-04 |
AU688792B2 (en) | 1998-03-19 |
KR960705572A (ko) | 1996-11-08 |
EP0725642B1 (en) | 1999-12-01 |
AU7716794A (en) | 1995-05-22 |
US5741523A (en) | 1998-04-21 |
CN1060042C (zh) | 2001-01-03 |
PT725642E (pt) | 2000-05-31 |
EP0725642A1 (en) | 1996-08-14 |
DE69421936T2 (de) | 2000-06-29 |
KR100335549B1 (ko) | 2002-11-29 |
JP3999263B2 (ja) | 2007-10-31 |
NZ273752A (en) | 1998-03-25 |
DE69421936D1 (de) | 2000-01-05 |
FI116270B (fi) | 2005-10-31 |
US5770230A (en) | 1998-06-23 |
NO961718L (no) | 1996-04-29 |
NO961718D0 (no) | 1996-04-29 |
GR3032817T3 (en) | 2000-06-30 |
FI961797A (fi) | 1996-04-26 |
ATE187071T1 (de) | 1999-12-15 |
CN1133561A (zh) | 1996-10-16 |
NO309126B1 (no) | 2000-12-18 |
ES2142409T3 (es) | 2000-04-16 |
FI961797A0 (fi) | 1996-04-26 |
DK0725642T3 (da) | 2000-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09504529A (ja) | 安定化したプロスタグランジンe▲下1▼ | |
JPH11503719A (ja) | 乾燥組成物 | |
US9168239B2 (en) | Levothyroxine formulations | |
KR101351668B1 (ko) | 신규 에포프로스테놀 제형 및 이의 제조방법 | |
CN101056623A (zh) | 稳定的头孢菌素衍生物冻干制剂 | |
KR20010034240A (ko) | 약학 조성물 | |
JP4142149B2 (ja) | バンコマイシンの凍結乾燥製剤 | |
JP2002505282A (ja) | ホスホリパーゼ阻害剤の[[3−(2−アミノ−1,2−ジオキソエチル)−2−エチル−1−フェニルメチル)−1h−インドール−4−イル]オキシ]酢酸ナトリウムを含む薬学的組成物 | |
JPH07196517A (ja) | 安定な凍結乾燥済みチオテパ組成物 | |
CN111228226A (zh) | 一种供注射用法匹拉韦的冻干制剂及其制备方法 | |
US5972912A (en) | Method for lyophilizing ifosfamide | |
EP4393480A1 (en) | Lyophilized formulation solution and lyophilized formulation, and method and use thereof | |
WO2008026556A1 (fr) | Préparation lyophilisée de 1-méthylcarbapenem | |
EP1166773A1 (en) | Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof | |
JP2023536509A (ja) | アクアポリン阻害剤の医薬組成物およびその製造方法 | |
JP3829874B2 (ja) | プロスタグランジン含有凍結乾燥品 | |
JP2003095955A (ja) | ヒアルロン酸ナトリウムの安定化固形組成物 | |
US20230225976A1 (en) | Lyophilized formulation containing cephalosporin having catechol group and the manufacturing method | |
CN116421569B (zh) | 一种注射用帕瑞昔布钠药物组合物及其制备方法 | |
JP2988631B2 (ja) | ホスホマイシンナトリウムの凍結乾燥製剤およびその製造法 | |
GB2167302A (en) | Stable lyophilized antibacterial preparations | |
US20030099693A1 (en) | Wafer | |
CN115998690A (zh) | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 | |
JP2004269401A (ja) | 凍結乾燥製剤 | |
JP2006117704A (ja) | プロスタグランジン含有凍結乾燥品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050607 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050818 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060815 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070717 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070809 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100817 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110817 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120817 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120817 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130817 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |